Apo-Gefitinib 250 mg

APO-GEFITINIB 250 MG tablets are a medication used to manage certain types of cancer. This oral treatment is designed to target specific proteins involved in cancer cell growth, offering a targeted approach to therapy.

APO-GEFITINIB 250 MG tablets are primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic markers. Gefitinib, the active ingredient, is often prescribed for patients who have tested positive for certain mutations. This medication is part of a broader category of cancer treatments known as tyrosine kinase inhibitors (TKIs), which work by interfering with the growth and spread of cancer cells.

Common effects of APO-GEFITINIB 250 MG tablets may include skin rash, diarrhea, and nausea. Some users might experience appetite loss or fatigue. These effects can vary widely among individuals and are not exhaustive. Always consult a healthcare provider for personalized advice.

APO-GEFITINIB 250 MG tablets should be handled with care, especially for those with pre-existing liver or lung conditions. It is important to follow the prescribed dosage and administration guidelines. Pregnant women or those planning to become pregnant should discuss the potential risks with their healthcare provider.

APO-GEFITINIB 250 MG tablets may interact with certain medications, including those metabolized by the liver's cytochrome P450 enzymes. Alcohol and other substances that affect liver function should be avoided. Always inform your healthcare provider about all medications and supplements you are taking.